专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20150293119A1 ASSESSING RENAL STRUCTURAL ALTERATIONS AND OUTCOMES 审中-公开
标题翻译：评估肾结构改变和成果
公开(公告)号：US20150293119A1
公开(公告)日：2015-10-15
申请号：US14367185
申请日：2012-10-11
申请人： Mayo Foundation for Medical Education and Research
发明人： Sasantha J. Sangaralingham , John C. Burnett, JR. , Alessandro Cataliotti , Denise M. Heublein
IPC分类号： G01N33/68 , A61K38/22
CPC分类号： G01N33/6893 , A61K38/2242 , A61K45/06 , C07K14/58 , G01N2333/58 , G01N2800/04 , G01N2800/042 , G01N2800/32 , G01N2800/324 , G01N2800/325 , G01N2800/347 , G01N2800/52 , G01N2800/56
摘要： This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.
摘要翻译：本文件提供了评估肾脏结构改变（例如肾纤维化，肾小球基底增厚，肾小球膜基质扩张，肿胀足细胞和脚部过程）的方法和材料以及参与评估结果的方法和材料。例如，使用尿CNP水平的方法和材料（例如，尿中血浆CNP比例）来确定哺乳动物是否正在发展肾结构改变（例如肾纤维化，肾小球基底增厚，肾小球膜基质扩张，肿胀足细胞和足部过程消除）以及使用尿CNP水平水平来鉴定具有增加的可能性经历不良结果的患者的方法和材料。

72. 发明申请

US20150290156A1 METHODS OF QUANTIFYING N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (CEDG) AND SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING CEDG 有权
标题翻译：量化N2-（1-羧甲基）-2'-脱氧鸟苷（CEDG）的方法和含有CEDG的寡核苷酸的合成
公开(公告)号：US20150290156A1
公开(公告)日：2015-10-15
申请号：US14536299
申请日：2014-11-07
申请人： CITY OF HOPE
发明人： Samuel RAHBAR , Timothy W. SYNOLD , John TERMINI
IPC分类号： A61K31/195 , G01N30/72 , A61N5/10 , A61K45/06
CPC分类号： A61K31/195 , A61K45/06 , A61N5/10 , G01N30/7233 , G01N30/7266 , G01N2030/045 , G01N2030/8827 , G01N2030/8868 , G01N2800/042
摘要： Methods of quantifying a N2-carboxyethyl-2′-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
摘要翻译：定量生物样品中N2-羧乙基-2'-脱氧鸟苷（CEdG）水平的方法并将这些水平与已知正常水平进行比较可以诊断许多疾病，包括糖尿病和癌症。方法还可以通过测量治疗前后的CEdG水平来确定疾病疗法是否有效。使用液相色谱电喷雾电离串联质谱法测定CEdG水平。

73. 发明授权

US09131903B2 Diabetes treatment support apparatus, diabetes treatment support method, diabetes treatment support program 有权
标题翻译：糖尿病治疗支持装置，糖尿病治疗支持方法，糖尿病治疗支持方案
公开(公告)号：US09131903B2
公开(公告)日：2015-09-15
申请号：US14377737
申请日：2012-11-12
申请人： OMRON HEALTHCARE CO., LTD.
发明人： Muneo Tokita , Satoshi Nakajima
IPC分类号： A61B5/00 , A61B5/145 , A61B5/1473 , G01N27/416 , G01N33/66 , G01N33/72 , G06F19/00
CPC分类号： A61B5/7278 , A61B5/14532 , A61B5/14546 , A61B5/1473 , A61B5/486 , A61B5/4866 , A61B5/7282 , A61B5/742 , G01N27/416 , G01N33/66 , G01N33/72 , G01N2800/042 , G06F19/00 , G16H40/63
摘要： A control unit obtains, from a memory unit, data of a plurality of pre-meal blood sugar levels that are blood sugar levels measured before meals and data of a plurality of post-meal blood sugar levels that are blood sugar levels measured after meals, calculates a pre-meal average value that is an average value of the plurality of pre-meal blood sugar levels, calculates a post-meal average value that is an average value of the plurality of post-meal blood sugar levels, calculates an average blood sugar level that is an average of the pre-meal average value and the post-meal average value, calculates an estimated HbA1c value using the average blood sugar level, and displays the calculated estimated HbA1c value in a display unit.
摘要翻译：控制单元从存储器单元获取餐前测量的血糖水平的多个餐前血糖水平的数据和饭后测量的血糖水平的多个膳食后血糖水平的数据，计算作为多个膳食前血糖水平的平均值的餐前平均值，计算作为多次餐后血糖水平的平均值的餐后平均值，计算平均血液作为餐前平均值和餐后平均值的平均值的糖水平，使用平均血糖水平计算估计的HbA1c值，并将计算出的估计HbA1c值显示在显示单元中。

74. 发明申请

US20150250854A1 VOLTAGE GATED CALCIUM CHANNEL BETA-SUBUNIT ANCHORING REGULATOR PROTEIN AND USES THEREOF 审中-公开
标题翻译：电压门控钙通道亚甲基锚定蛋白调节蛋白及其用途
公开(公告)号：US20150250854A1
公开(公告)日：2015-09-10
申请号：US14664486
申请日：2015-03-20
申请人： Agency for Science, Technology and Research
发明人： Pascal Beguin , Walter Hunziker
IPC分类号： A61K38/17 , C07K16/28
CPC分类号： A61K38/1709 , A61K38/00 , C07K14/4702 , C07K14/705 , C07K16/28 , C07K2317/76 , G01N33/6872 , G01N2800/042 , Y10T436/143333
摘要： The present invention relates to a novel gene encoding a protein termed voltage gated calcium channels β subunit anchoring regulator protein (VDCC BARP) or a peptide fragments thereof. The present invention also relates to the use of VDCC BARP in modulation of voltage gated calcium channels via altering the concentration of VDCC BARP or a peptide fragments thereof.
摘要翻译：本发明涉及编码称为电压门控钙通道的蛋白质的新型基因亚单位锚定调节蛋白（VDCC BARP）或其肽片段。本发明还涉及VDCC BARP通过改变VDCC BARP或其肽片段的浓度来调节电压门控钙通道的用途。

75. 发明申请

US20150247839A1 CMPF AS A BIOMARKER FOR DIABETES AND ASSOCIATED METHODS 有权
标题翻译： CMPF作为糖尿病和相关方法的生物标记
公开(公告)号：US20150247839A1
公开(公告)日：2015-09-03
申请号：US14429977
申请日：2013-09-20
申请人： THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
发明人： Michael Wheeler , Kacey Prentice , Feihan Dai , Ravi Retnakaran
IPC分类号： G01N33/50 , G01N33/53 , A61K31/196 , A61K31/43 , A61K38/17 , A61K31/195
CPC分类号： G01N33/5005 , A61K31/195 , A61K31/196 , A61K31/198 , A61K31/43 , A61K38/177 , C07D307/68 , G01N33/5023 , G01N33/507 , G01N33/5308 , G01N2030/8822 , G01N2800/042 , G01N2800/50 , G01N2800/52 , Y10T436/142222
摘要： Provided are methods for identifying or monitoring a subject having, or at risk of developing, impaired glucose homeostasis. Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is shown to be a biomarker for impaired glucose homeostasis and/or conditions characterized by β-cell dysfunction. Comparing a test level of CMPF in a subject to a control level identifies subjects having, or at risk of developing, impaired glucose homeostasis. Also provided are methods of causing impaired glucose homeostasis or β-cell dysfunction and methods of screening for compounds that affect the activity of β-cells. Also provided are methods for the treatment of β-cell dysfunction by reducing the physiological levels of CMPF in a subject as well as the use of a OAT modulator for the treatment of β-cell dysfunction.
摘要翻译：提供用于鉴定或监测具有或有发展为葡萄糖体内平衡受损的风险的受试者的方法。羧基-4-甲基-5-丙基-2-呋喃丙酸（CMPF）显示为葡萄糖体内平衡受损和/或以细胞功能障碍为特征的病症的生物标志物。将受试者中的CMPF的测试水平与对照水平进行比较，以识别具有发展中的葡萄糖体内平衡受损的风险。还提供了导致葡萄糖体内平衡受损或细胞功能障碍的方法以及筛选影响细胞活性的化合物的方法。还提供了通过降低受试者中CMPF的生理水平以及使用OAT调节剂治疗细胞功能障碍来治疗细胞功能障碍的方法。

76. 发明申请

US20150193587A1 DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：US20150193587A1
公开(公告)日：2015-07-09
申请号：US14559058
申请日：2014-12-03
申请人： Health Diagnostic Laboratory, Inc.
发明人： Mickey S. URDEA , Michael P. McKenna , Patrick A. Arensdorf
IPC分类号： G06F19/00
CPC分类号： G16H50/30 , G01N33/48714 , G01N33/6893 , G01N2800/042 , G01N2800/52 , G06Q50/22 , Y02A90/22
摘要： The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.

77. 发明申请

US20150087806A1 GLYCOPEPTIDE AND USES THEREOF 有权
标题翻译：甘氨酸及其用途
公开(公告)号：US20150087806A1
公开(公告)日：2015-03-26
申请号：US14558088
申请日：2014-12-02
申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
发明人： GEERT-JAN BOONS , THERESE BUSKAS , SAMPAT INGALE , MARGARETHA WOLFERT
IPC分类号： A61K47/48 , A61K39/385
CPC分类号： C07K16/44 , A61K9/127 , A61K38/00 , A61K39/0008 , A61K39/0011 , A61K47/646 , A61K2039/545 , A61K2039/55511 , A61K2039/55555 , A61K2039/57 , A61K2039/6018 , A61K2039/6075 , C07K9/00 , C07K14/22 , C07K14/4727 , C07K16/3076 , C07K2317/34 , C12N2740/16011 , C12N2740/16134 , G01N33/92 , G01N2400/02 , G01N2800/042 , G01N2800/2821
摘要： A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.
摘要翻译：包含用作治疗或预防性疫苗的碳水化合物组分，肽组分和脂质组分的糖脂肽。还提供了识别本发明的糖脂肽的单克隆和多克隆抗体及其用途。

78. 发明申请

US20150064148A1 METHOD FOR TREATING OR PREVENTING A PANCREATIC DYSFUNCTION 有权
标题翻译：用于治疗或预防胰腺功能障碍的方法
公开(公告)号：US20150064148A1
公开(公告)日：2015-03-05
申请号：US14535827
申请日：2014-11-07
申请人： Silviu Itescu , Ravi Krishnan
发明人： Silviu Itescu , Ravi Krishnan
IPC分类号： A61K35/12 , A61K45/06
CPC分类号： A61K35/545 , A61K35/12 , A61K45/06 , C12N5/0676 , G01N33/66 , G01N33/6893 , G01N33/74 , G01N2333/47 , G01N2333/62 , G01N2800/042
摘要： The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
摘要翻译：本发明提供了一种在有需要的受试者中改善胰腺功能的方法，所述方法包括给予受试者STRO-1 +细胞和/或其后代细胞和/或由其衍生的可溶性因子。本发明的方法可用于治疗和/或预防和/或延缓由胰腺功能障碍引起或与胰腺功能障碍相关的疾病的发作或进展，例如由胰腺的内分泌或外分泌功能异常引起。

79. 发明授权

US08968706B2 Methods for diagnosing and treating loss or distortion of taste 有权
标题翻译：诊断和治疗口味损失或扭曲的方法
公开(公告)号：US08968706B2
公开(公告)日：2015-03-03
申请号：US13932613
申请日：2013-07-01
申请人： Robert I. Henkin
发明人： Robert I. Henkin
IPC分类号： A61K49/00 , A61K35/24 , C12P19/30 , G01N33/567 , G01N33/566 , G01N33/68 , A61K31/522 , G01N33/574 , G01N33/576 , C12Q1/68
CPC分类号： A61K31/522 , A61K9/0043 , A61K31/4709 , C12Q1/6883 , C12Q1/6886 , C12Q2600/118 , G01N33/566 , G01N33/57449 , G01N33/576 , G01N33/6893 , G01N2333/525 , G01N2333/70575 , G01N2800/042 , G01N2800/14 , G01N2800/52 , Y02A50/463 , Y02A50/54
摘要： The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease.The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.
摘要翻译：本发明涉及一种检测鼻分泌物中的生物物质的方法，并且在检测到生物物质与生物物质与呼吸系统疾病无关之后诊断疾病。本发明还提供了在检测生物物质和/或诊断疾病之后的疾病的治疗。在一些实施方案中，疾病是癌症，肝炎，气味丧失，味觉丧失，糖尿病和麻风病。本发明还提供了用于诊断疾病的试剂盒。本发明包括分析来自鼻子的样品用于检测生物物质的方法。特别地，收集鼻分泌物或鼻粘液并分析生物物质。该分析结果适用于诊断，预后和治疗干预适合性的测定。

80. 发明申请

US20150037822A1 MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES 有权
标题翻译：食品糖尿病的主要生物标志物
公开(公告)号：US20150037822A1
公开(公告)日：2015-02-05
申请号：US14516383
申请日：2014-10-16
申请人： DiabetOmics, LLC
发明人： Srinivasa R. Nagalla
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N33/74 , G01N33/76 , G01N2333/471 , G01N2333/78 , G01N2800/042 , G01N2800/368 , G01N2800/60
摘要： Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex. In some embodiments, the proteomic profile may also include information on the expression of adiponectin, sex hormone binding globulin (SHBG), C-reactive protein (CRP), a ratio of human chorionic gonadotropin (hCG) to placental lactogen, or a combination thereof.
摘要翻译：本文的实施方案涉及用于胎儿/母亲健康的筛选工具领域，更具体地，涉及用于妊娠糖尿病的生物标志物的领域。在各种实施方案中，所述方法可以提供用于妊娠糖尿病的非侵入性和最小侵入性筛选工具，其涉及检测测试样品相对于参考样品的蛋白质组图谱的变化。在具体实施方案中，该方法可以包括确定来自受试者的测试样品的蛋白质组图谱是否包括妊娠糖尿病特征的至少一个表达特征，其中蛋白质组学特征包括关于糖基化纤连蛋白和糖基化PSG的表达的信息，例如信息纤连蛋白-SNA或纤连蛋白 - 抗体复合物水平，PSG-AAL或PSG-抗体复合物。在一些实施方案中，蛋白质组学特征还可以包括关于脂联素，性激素结合球蛋白（SHBG），C-反应蛋白（CRP），人绒毛膜促性腺激素（hCG）与胎盘乳糖的比例或其组合的表达的信息。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式